{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:43:47Z","timestamp":1761061427017},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,7]]},"DOI":"10.7759\/cureus.15491","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:32:22Z","timestamp":1623069142000},"source":"Crossref","is-referenced-by-count":2,"title":["Reactivation of Pulmonary Tuberculosis During Treatment of Chronic Myelomonocytic Leukemia"],"prefix":"10.7759","author":[{"given":"Jay","family":"Pescatore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Moturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Hernandez-Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. (2000). Accessed. April 19, 2021: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr4906a1.htm."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1499904","article-title":"The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome\/myeloproliferative neoplasm: a large population-based cohort study","volume":"60","author":"Ganzel C","year":"2019","unstructured":"Ganzel C, Silverman B, Chemtob D, Ben Shoham A, Wiener-Well Y. The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome\/myeloproliferative neoplasm: a large population-based cohort study. Leuk Lymphoma. 2019, 60:720-5. 10.1080\/10428194.2018.1499904","journal-title":"Leuk Lymphoma"},{"key":"ref3","article-title":"Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances","volume":"90","author":"Silva FA","year":"2005","unstructured":"Silva FA, Matos JO, de Q Mello FC, Nucci M. Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances. Haematologica. 2005, 90:1110-5.","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmyco.2015.05.015","article-title":"Reactivation of pulmonary tuberculosis during cancer treatment","volume":"4","author":"Jacobs RE","year":"2015","unstructured":"Jacobs RE, Gu P, Chachoua A. Reactivation of pulmonary tuberculosis during cancer treatment. Int J Mycobacteriol. 2015, 4:337-40. 10.1016\/j.ijmyco.2015.05.015","journal-title":"Int J Mycobacteriol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-017-0047-y","article-title":"How to diagnose early 5-Azacytidine-induced pneumonitis: a case report","volume":"4","author":"Misra SC","year":"2017","unstructured":"Misra SC, Gabriel L, Nacoulma E, Dine G, Guarino V. How to diagnose early 5-Azacytidine-induced pneumonitis: a case report. Drug Saf Case Rep. 2017, 4:4. 10.1007\/s40800-017-0047-y","journal-title":"Drug Saf Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.04.024","article-title":"Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review","volume":"36","author":"Thorpe M","year":"2012","unstructured":"Thorpe M, Montalv\u00e3o A, Pierdomenico F, Moita F, Almeida A. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res. 2012, 36:1071-3. 10.1016\/j.leukres.2012.04.024","journal-title":"Leuk Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa R","year":"2011","unstructured":"Costa R, Abdulhaq H, Haq B, et al.. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011, 117:2690-6. 10.1002\/cncr.25759","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/418292","article-title":"5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity","volume":"2014","author":"St\u00fcbig T","year":"2014","unstructured":"St\u00fcbig T, Badbaran A, Luetkens T, et al.. 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm. 2014, 2014:418292. 10.1155\/2014\/418292","journal-title":"Mediators Inflamm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/58715-reactivation-of-pulmonary-tuberculosis-during-treatment-of-chronic-myelomonocytic-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:41Z","timestamp":1707507281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/58715-reactivation-of-pulmonary-tuberculosis-during-treatment-of-chronic-myelomonocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.15491","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,7]]}}}